This article is more than 5 years old. Information may no longer be current.
miR-378 may be linked to treatment response in ovarian cancer
Click Here to Manage Email Alerts
42nd Annual Meeting of the Society for Gynecologic Oncologists
ORLANDO — Researchers have found that miR-378 may be associated with treatment response after chemotherapy with bevacizumab in recurrent ovarian cancer.
“MicroRNA has been shown to regulate gene expression, but more specifically in ovarian cancer it has been shown to impact survival and also predict response to chemotherapy in ovarian cancer, as well as in pancreatic, lung, breast, prostate and colorectal malignancies,” according to John Chan, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, who presented findings of the study. “However, there is no information of its ability to predict response to biologic agents like bevacizumab.”
Data on demographics, clinicopathology, survival and genomics were extracted from The Cancer Genome Atlas. All patients had recurrent ovarian cancer and were treated with chemotherapy plus bevacizumab (Avastin, Genentech/Roche). Al of the patients had serous histology and had undergone primary surgery. The median time to recurrence was 11.3 months and the 5-year OS was 51%.
The most common chemotherapy regimens used included cyclophosphamide, doxorubicin and platinum-taxane combination, each with bevacizumab. The median time to recurrence after treatment was 3.34 months. Patients who had a treatment-free interval of greater than 3 months had a 5-year OS of 78.3% vs. 16.7% for patients who had a shorter treatment-free interval.
The researchers found that upregulation of miR-128 and miR-375, as well as downregulation of miR-214, miR-145, miR-21, miR-378 and miR-375 were associated with longer PFS after treatment with chemotherapy and bevacizumab. The six-month PFS after treatment with chemotherapy and bevacizumab was 77.8% in patients who had downregulation of miR-378, compared with 33.6% in patients who had normal miR-378.
On multivariate analysis, treatment-free interval and miR-378 expression remained as independent predictors of response to treatment with chemotherapy and bevacizumab.
Disclosures: The researchers report no disclosures.
For more information:
- Chan J. #6. 42nd Annual Meeting of the Society for Gynecologic Oncologists. March 6-9, 2011. Orlando, Fla.
 |
Follow HemOncToday.com on Twitter. |